Allergic diseases are among the most prevalent immune-mediated diseases,
with incidences of well over 20% of the population in industrialized countries.
Nevertheless, the question of whether allergies should be considered as a risk factor
for exposure to nanomaterials has rarely been addressed. Experimental studies have
attempted to improve allergy therapy by combining allergens with various
nanomaterials, which may lead to a beneficial re-direction of the immune system.
Binding to nanoparticles may for allergens – as for other proteins – lead to structural
changes or modification of other properties. We assess here the state of knowledge
about biological effects deriving from the combination of nanoparticles with allergens.
Keywords: Allergy, sensitization, effector function, allergen-specific immunotherapy, SCIT, SLIT, immunomodulation,
Rights & PermissionsPrintExport